Novo Nordisk – major shareholder announcement

Bagsværd, Denmark, 14 March 2022 – Novo Nordisk today announced that the company has been notified by BlackRock, Inc. (Blackrock) that Blackrock as of 8 March 2022 holds B shares equal to below 5% of the entire share capital of Novo Nordisk. The announcement is in accordance with section 30 of the Danish Capital Markets Act.

The total B shares according to section 38 of the Danish Capital Markets Act, and other financial instruments according to section 39(2)(1) of the Danish Capital Markets Act and financial instruments with similar effects according to section 39(2)(2) of the Danish Capital Markets Act held by Blackrock correspond to below 5% of the entire share capital and below 5% of the voting rights.

For a full chain of controlled undertakings through which the voting rights and/or the financial instruments are held, please see the annex.

About Novo NordiskNovo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 47,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO).

Further information

Media:     
Ambre Brown Morley +45 3079 9289 abmo@novonordisk.com
Michael Bachner (US)   +1 609 664 7308  mzyb@novonordisk.com 
     
Investors:     
Daniel Muusmann Bohsen  +45 3075 2175  dabo@novonordisk.com 
Ann Søndermølle Rendbæk  +45 3075 2253  arnd@novonordisk.com 
David Heiberg Landsted  +45 3077 6915  dhel@novonordisk.com 
Jacob Martin Wiborg Rode  +45 3075 5956  jrde@novonordisk.com 
Mark Joseph Root (US)  +1 848 213 3219  mjhr@novonordisk.com 

Company announcement No 23 / 2022

Annex

Name % of voting rights if it equals or is higher than the notifiable threshold % of voting rights through financial instruments if it equals or is higher than the notifiable threshold Total of both if it equals or is higher than the notifiable threshold
BlackRock Japan Co., Ltd.     Below 5%
BlackRock Investment Management, LLC     Below 5%
BlackRock Investment Management (UK) Limited     Below 5%
BlackRock Investment Management (Australia) Limited     Below 5%
BlackRock International Limited     Below 5%
BlackRock Institutional Trust Company, National Association     Below 5%
BlackRock Fund Advisors     Below 5%
BlackRock Financial Management, Inc.     Below 5%
BlackRock Asset Management North Asia Limited     Below 5%
BlackRock Asset Management Deutschland AG     Below 5%
BlackRock Asset Management Canada Limited     Below 5%
BlackRock Advisors, LLC     Below 5%
BlackRock Advisors (UK) Limited     Below 5%
BlackRock (Singapore) Limited     Below 5%
BlackRock Asset Management Ireland Limited     Below 5%
Aperio Holdings, LLC     Below 5%

Attachment

  • CA220314_Major_shareholder_information
Novo Nordisk (TG:NOVC)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Novo Nordisk Charts.
Novo Nordisk (TG:NOVC)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Novo Nordisk Charts.